HR Execs on the Move

Broadstep

www.broadstep.com

 
CompassionWe embrace each persons’ journey, celebrating unique perspectives and situations free of judgment.TeamworkWe are one team. We celebrate each others’ successes and work together to overcome challenges.ExcellenceWe grow with each other, so we p...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kyle Peterson
VP, Finance and Operations Profile

Similar Companies

Mixhers

Mixhers is a company that provides supplements designed specifically for womens health and wellness, with each product carefully crafted to support women in all stages of life.

Robinson Pharma

Since 1989 Robinson Pharma, Inc. (RPI) has served domestic and international marketers of vitamins and dietary supplements. From its humble beginnings as a contract packager, RPI has grown to become a significant entity in the dietary supplement industry

Stellar Pharmaceuticals Inc

Stellar Pharmaceuticals Inc is a London, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

MHR

The mission of Mental Health Resources, Inc. is to foster hope, health and recovery for those affected by mental illness.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.